Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-13, Stock:ABBV, The news for the past five days is as follows:
2019-03-06: NEWS1: Bio-Path stock soars in active trade after announcing Phase 2 trial update.NEWS2: 7 Stocks That Can Outperform In a Post QE Market.NEWS3: Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice.NEWS4: Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice.NEWS5: Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice.NEWS6: What Are Mylan’s Key Growth Drivers in Fiscal 2019?.
2019-03-07: NEWS1: The Kiplinger Dividend 15 Is On a Roll.NEWS2: Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed.NEWS3: Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed.NEWS4: UPDATE: Bio-Path stock gains another 130% on Thursday.NEWS5: AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients.NEWS6: Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed.NEWS7: 2 Biotech Stocks With Major Incoming Catalysts.NEWS8: 2 Biotech Stocks With Major Incoming Catalysts.NEWS9: 2 Biotech Stocks With Major Incoming Catalysts.
2019-03-08: NEWS1: The Kiplinger Dividend 15 Is On a Roll.NEWS2: The Kiplinger Dividend 15 Is On a Roll.NEWS3: Don’t Abandon Gilead Stock After Weak Q4 Results.NEWS4: Don’t Abandon Gilead Stock After Weak Q4 Results.NEWS5: Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs.NEWS6: Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC.NEWS7: Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC.NEWS8: Don’t Abandon Gilead Stock After Weak Q4 Results.NEWS9: Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC.
2019-03-11: NEWS1: AbbVie (ABBV) Gains But Lags Market: What You Should Know.NEWS2: Should Value Investors Consider Abbvie (ABBV) Stock Now?.NEWS3: Should Value Investors Consider Abbvie (ABBV) Stock Now?.NEWS4: Should Value Investors Consider Abbvie (ABBV) Stock Now?.
2019-03-12: NEWS1: Takeda's Entyvio Tops AbbVie's Humira in Patients With Ulcerative Colitis.NEWS2: Noteworthy Tuesday Option Activity: AMG, NRG, ABBV.NEWS3: Noteworthy Tuesday Option Activity: AMG, NRG, ABBV.NEWS4: Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval.NEWS5: Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval.NEWS6: Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval.NEWS7: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS8: AbbVie (ABBV) Gains But Lags Market: What You Should Know.NEWS9: AbbVie (ABBV) Gains But Lags Market: What You Should Know.

Answer: Rise